keyword
MENU ▼
Read by QxMD icon Read
search

non radiographic axial spondyloarthritis

keyword
https://www.readbyqxmd.com/read/28197884/therapies-of-early-advanced-and-late-onset-forms-of-axial-spondyloarthritis-and-the-need-for-treat-to-target-strategies
#1
REVIEW
Nurullah Akkoc, Gercek Can, Salvatore D'Angelo, Angela Padula, Ignazio Olivieri
PURPOSE OF REVIEW: This study aims to provide an update on current status of pharmacological therapies in early and advanced stages of axial spondyloarthritis (axSpA), as well as its late onset forms, and to discuss the need for treat to target strategies in this entity. RECENT FINDINGS: Efficacy of TNF inhibitors has been assessed in randomized controlled trials in axSpA, which included patients who had non-radiographic axSpA according to the ASAS classification criteria...
February 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28176964/efficacy-and-safety-of-biological-and-targeted-synthetic-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#2
Alexandre Sepriano, Andrea Regel, Désirée van der Heijde, Jürgen Braun, Xenofon Baraliakos, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
OBJECTIVES: To update the evidence for the efficacy and safety of (b)biological and (ts)targeted-synthetic disease-modifying anti-rheumatic drugs (DMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2016 update of the Assessment of SpondyloArthritis international Society/European League Against Rheumatism (ASAS/EULAR) recommendations for the management of axSpA. METHODS: Systematic literature review (2009-2016) for randomised controlled trials (RCT), including long-term extensions, strategy trials and observational studies (the latter was only for safety assessment and a comparator was required)...
2017: RMD Open
https://www.readbyqxmd.com/read/28124744/-inflammatory-spinal-diseases-axial-spondyloarthritis-central-importance-of-imaging
#3
X Baraliakos, M Fruth, U Kiltz, J Braun
The diagnosis of axial spondyloarthritis (axSpA) includes classical ankylosing spondylitis (AS) as well as earlier stages and abortive courses of the disease, in which structural alterations have not yet occurred. These are classified as non-radiographic axSpA (nr-axSpa). Inflammatory changes in the entire axial skeleton are characteristic for axSpA and can be visualized by magnetic resonance imaging (MRI), while in most patients structural alterations, such as new bone formation with syndesmophytes and ankylosis develop in the later course of the disease...
January 26, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28110981/axial-spondyloarthritis
#4
REVIEW
Joachim Sieper, Denis Poddubnyy
The term axial spondyloarthritis covers both patients with non-radiographic and radiographic axial spondyloarthritis, which is also termed ankylosing spondylitis. The disease usually starts in the third decade of life with a male to female ratio of two to one for radiographic axial spondyloarthritis and of one to one for non-radiographic axial spondyloarthritis. More than 90% heritabilty has been estimated, the highest genetic association being with HLA-B27. The pathogenic role of HLA-B27 is still not clear although various hypotheses are available...
January 19, 2017: Lancet
https://www.readbyqxmd.com/read/28099816/new-treatment-options-and-emerging-drugs-for-axial-spondyloarthritis-biological-and-targeted-synthetic-agents
#5
Eric Toussirot
Ankylosing spondylitis (AS) and axial spondyloarthritis (ax SpA) are chronic inflammatory diseases mainly involving the axial skeleton. Pharmacological treatments for AS and ax SpA usually include local glucocorticoid injections, NSAIDs and anti-TNFα agents. Since around 30% to 40% of patients are non responders or intolerant to anti-TNFα agents, we need new therapeutic options for AS and ax SpA. Areas covered: This review describes the new biological agents that can be used or are in development for AS or ax SpA as well as emerging synthetic targeted drugs...
February 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28087505/2016-update-of-the-asas-eular-management-recommendations-for-axial-spondyloarthritis
#6
Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados, Floris van Gaalen, Pál Géher, Irene van der Horst-Bruinsma, Robert D Inman, Merryn Jongkees, Uta Kiltz, Tore K Kvien, Pedro M Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compàn, Salih Ozgocmen, Fernando M Pimentel-Santos, John Reveille, Martin Rudwaleit, Jochen Sieper, Percival Sampaio-Barros, Dieter Wiek, Jürgen Braun
To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009...
January 13, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28064208/work-disability-in-non-radiographic-axial-spondyloarthritis-patients-before-and-after-start-of-anti-tnf-therapy-a-population-based-regional-cohort-study-from-southern-sweden
#7
Johan K Wallman, Anna Jöud, Tor Olofsson, Lennart T H Jacobsson, Henning Bliddal, Lars E Kristensen
OBJECTIVE: The aim was to assess work-loss days before and after commencement of anti-TNF treatment in patients with non-radiographic axial spondylarthritis (nr-axSpA). METHODS: Bionaïve nr-axSpA patients (n = 75), aged 17-62 years, fulfilling the Assessment of SpondyloArthritis international Society criteria for axial spondyloarthritis and starting anti-TNF treatment during 2004-11, were retrieved from the observational South Swedish Arthritis Treatment Group study...
January 7, 2017: Rheumatology
https://www.readbyqxmd.com/read/28035438/should-axial-spondyloarthritis-without-radiographic-changes-be-treated-with-anti-tnf-agents
#8
REVIEW
Andrew Keat, Alexander N Bennett, Karl Gaffney, Helena Marzo-Ortega, Raj Sengupta, Tamara Everiss
A spectrum of disease extends beyond the rigid confines of ankylosing spondylitis (AS). Axial spondyloarthritis (axSpA) encompasses non-radiographic axSpA (nr-axSpA) in individuals without established radiographic changes but with other clinical/imaging axSpA features and AS in those with definite sacroiliac joint changes on pelvic X-rays. A broad consensus about the management of nr-axSpA is emerging among clinicians, but the evidence base remains open to question. To explore whether nr-axSpA and AS should be treated similarly, we examined the literature on their prevalence, natural history, disease burden, and treatment...
March 2017: Rheumatology International
https://www.readbyqxmd.com/read/27997346/efficiency-of-treatment-with-non-steroidal-anti-inflammatory-drugs-according-to-current-recommendations-in-patients-with-radiographic-and-non-radiographic-axial-spondyloarthritis
#9
Xenofon Baraliakos, Uta Kiltz, Soeren Peters, Heiner Appel, Friedrich Dybowski, Manfred Igelmann, Ludwig Kalthoff, Dietmar Krause, Hans-Juergen Menne, Ertan Saracbasi-Zender, Elmar Schmitz-Bortz, Mathura Vigneswaran, Juergen Braun
OBJECTIVE: NSAIDs are first-line therapy in axial SpA (axSpA). The proportion of patients responding to NSAIDs and differences between AS and non-radiographic axSpA (nr-axSpA) in this regard have not been studied in detail to date. The aim of this study was to examine the proportion of patients with AS and nr-axSpA responding to NSAIDs according to current treatment recommendations. METHODS: Consecutive anti-TNF-naïve patients with nr-axSpA and AS (n = 50 each) were included if their BASDAI score was ⩾4 without having received maximal NSAID doses...
January 2017: Rheumatology
https://www.readbyqxmd.com/read/27991410/reply-to-the-editorial-can-we-currently-and-confidently-assess-the-true-burden-of-illness-due-to-non-radiographic-axial-spondyloarthritis-by-s-van-der-linden-and-m-a-khan
#10
Joachim Sieper, Robert Wood, Sumesh Kachroo
****************************************************************************.
November 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27991409/can-we-currently-and-confidently-assess-the-true-burden-of-illness-due-to-non-radiographic-axial-spondyloarthritis
#11
EDITORIAL
Sjef van der Linden, Muhammad A Khan
****************************************************************************.
November 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27979416/the-effect-of-smoking-on-clinical-and-structural-damage-in-patients-with-axial-spondyloarthritis-a-systematic-literature-review
#12
REVIEW
Virginia Villaverde-García, Tatiana Cobo-Ibáñez, Gloria Candelas-Rodríguez, Daniel Seoane-Mato, Petra Díaz Del Campo-Fontecha, Mercedes Guerra, Santiago Muñoz-Fernández, Juan D Cañete
OBJECTIVES: To evaluate the association between smoking and clinical parameters and structural damage in axial spondyloarthritis (axSpA). METHODS: We systematically searched MEDLINE, EMBASE and Cochrane Library till November 2015. We selected articles that analysed the smoking impact on disease activity, functional status, structural damage, physical mobility and life quality. Independent extraction of articles by 2 authors using predefined data fields was performed...
November 16, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27974096/positive-correlation-between-inflammation-on-sacroiliac-joint-mri-and-serum-c-terminal-telopeptide-of-type-i-collagen-in-ankylosing-spondylitis-but-not-in-non-radiographic-axial-spondyloarthritis
#13
Kwi Young Kang, Joon-Yong Jung, Yeon Sik Hong, Ji Hyeon Ju, Sung-Hwan Park
OBJECTIVES: To identify the clinical disease activity scores and laboratory markers that best reflect magnetic resonance imaging (MRI)-determined sacroiliac joint (SIJ) inflammation in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). METHODS: This cross-sectional study included all consecutive patients who presented with axial spondyloarthritis in 2013-2015. All underwent SIJ MRI. The bone marrow oedema in the inflammatory lesions on MRI was scored using the SPondyloArthritis Research Consortium of Canada (SPARCC) method...
December 14, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27971814/a-network-metanalysis-to-compare-biologic-agents-in-the-treatment-of-non-radiographic-axial-spondyloarthritis
#14
A Migliore
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971766/certolizumab-pegol-is-associated-with-long-term-improvements-in-patient-reported-outcomes-in-axial-spondyloarthritis-patients-including-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-4-year-outcomes-from-the-rapid-axspa-study
#15
J Sieper, A Kivitz, A van Tubergen, A Deodhar, K Harris, T Nurminen, R Landewé
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971501/long-term-improvements-in-workplace-and-household-productivity-and-social-participation-over-4-years-of-certolizumab-pegol-treatment-in-patients-with-axial-spondyloarthritis-including-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis
#16
D van der Heijde, J Braun, M Rudwaleit, R Landewé, O Purcaru, A Kavanaugh
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971466/the-cost-effectiveness-of-tumour-necrosis-factor-%C3%AE-inhibitors-for-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis
#17
E Sideris, M Soares, S Palmer
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970595/the-importance-of-model-conceptualisation-a-case-study-in-ankylosing-spondylitis-as-and-non-radiographic-axial-spondyloarthritis-nr-axspa
#18
E Sideris, M Soares, S Palmer
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27887637/clinical-improvement-and-reduction-in-serum-calprotectin-levels-after-an-intensive-exercise-programme-for-patients-with-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis
#19
Andrea Levitova, Hana Hulejova, Maja Spiritovic, Karel Pavelka, Ladislav Senolt, Marketa Husakova
BACKGROUND: The efficacy of exercise therapy for ankylosing spondylitis (AS) is well-documented, but dearth of information is for non-radiographic axial spondyloarthritis (nr-axSpA). Biomarkers like serum calprotectin, interleukins IL-6, IL-17 and tumour necrosis factor (TNF)-α may reflect the disease activity of axial spondyloarthritis (axSpA). In this study, we investigated clinical and laboratory parameters of both axSpA subgroups in response to intensive physical exercise. METHODS: Altogether, 46 patients with axSpA, characterised according to the Assessment of SpondyloArthritis International Society criteria as having nr-axSpA or AS underwent 6-month exercise programme...
November 25, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27863065/efficacy-and-safety-of-etanercept-in-patients-from-latin-america-central-europe-and-asia-with-early-non-radiographic-axial-spondyloarthritis
#20
James Cheng-Chung Wei, Wen-Chan Tsai, Gustavo Citera, Sameer Kotak, Lyndon Llamado
AIM: To evaluate etanercept in patients from Latin America, Central/Eastern Europe, and Asia with non-radiographic axial spondyloarthritis (nr-axSpA). METHODS: A subset analysis was performed on nr-axSpA patients from Argentina, Colombia, the Czech Republic, Hungary, Russia and Taiwan who were enrolled in EMBARK (NCT01258738). Patients received either etanercept 50 mg or placebo once weekly. The primary endpoint was proportion of patients achieving 40% improvement from baseline based on Assessment of SpondyloArthritis International Society (ASAS) criteria...
November 11, 2016: International Journal of Rheumatic Diseases
keyword
keyword
111757
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"